CYP17A1 and prostate carcinoma: Since androgens are one of the main driving forces of prostate cancer, other than chemotherapeutic agents such as docetaxel and cabazitaxel, the androgen receptor (AR) and steroid biosynthesizing cytochrome P450 17A1 (CYP17A1) have been the primary targets of PCa treatment [9].